Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 1,307 trials

Heart Failure: Colchicine Study

We are investigating whether colchicine can improve health status in people with heart failure compared to a placebo. This study aims to see if it helps patients feel better based on specific health questionnaires.

Heart Failure with Preserved Ejection Fraction>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Menopausal Women with Breast Cancer: Prasterone Therapy

We are studying whether a vaginal treatment can improve urinary and vaginal symptoms in menopausal women with a history of breast cancer or those currently on hormone therapy. The goal is to see how this therapy affects their quality of life and overall wellbeing.

Breast CancerGenitourinary Syndrome of Menopause≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncologyUrology

Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

Dominant Optic Atrophy>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurologyOphthalmology

Cytomegalovirus Treatment: Letermovir and Valganciclovir Combination

We are studying whether a combination of letermovir and valganciclovir helps kidney transplant recipients with CMV infections achieve better viral response than valganciclovir alone.

Cytomegalovirus InfectionKidney Transplant>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesInfectious DiseasesNephrology

Limited-Stage Small-Cell Lung Cancer: Tarlatamab Study

We are studying whether tarlatamab can improve survival and prevent disease progression in patients with limited-stage small-cell lung cancer after chemoradiation therapy. Participants will receive either tarlatamab or a placebo to compare their effects.

Limited-Stage Small-Cell Lung CancerConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Lung Cancer: V940 and Pembrolizumab Study

We are studying the effects of a new treatment combining V940 with pembrolizumab for patients with resectable stage II to IIIB lung cancer. The goal is to see if this combination improves disease-free survival compared to a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsInvestigational MedicinesCost ReimbursementOncologyPulmonology

Long-Term Safety Study of Ongoing Treatment with Study Drugs

We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.

Metastatic Breast CancerMetastatic Non-Small Cell Lung CancerHER2 Positive Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Treatment Study

We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.

Post-Kidney Transplant Diabetes>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDiabetologyNephrology

Chronic Kidney Disease: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone for adults with chronic kidney disease and high blood pressure. The trial will assess its impact on kidney health and heart-related risks.

Chronic Kidney DiseaseHypertension>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Parkinson’s Disease vs. Multiple System Atrophy: Imaging Study

We are comparing two imaging methods to see which one better identifies Parkinson’s disease and multiple system atrophy. This may help improve diagnosis for patients with these conditions.

Parkinson's DiseaseAlzheimer's DiseaseMultiple Systems Atrophy - Parkinsonian Variant>2 yearsEfficacy phase (II)Confirmation phase (III)NeurologyOtolaryngology

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology